trending Market Intelligence /marketintelligence/en/news-insights/trending/2e-LV7-EkU-Ja0BqQ7D6zQ2 content esgSubNav
In This List

Avadel's hospital product candidate accepted for priority review by US FDA

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Avadel's hospital product candidate accepted for priority review by US FDA

Avadel Pharmaceuticals PLC said the U.S. Food and Drug Administration accepted the new drug application for the company's hospital product candidate AV001 and granted it priority review.

The U.S. regulator will decide on Avadel's product candidate by Sept. 15. The Dublin-based company did not disclose what indication the product will be used for.